Generated by AI
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for human disease. The company’s current portfolio centers on therapies for cardiometabolic disorders, neuropathic pain, and other chronic conditions, with products and candidates spanning commercial, clinical, and preclinical stages. Its marketed medicine INPEFA (sotagliflozin) is used in cardiometabolic care, while development programs include pilavapadin for neuropathic pain and LX9851 for obesity and related metabolic disorders. Lexicon Pharmaceuticals also applies its gene-science and target-biology expertise to advance drug candidates aimed at genetically defined pathways, reflecting a research-driven model that links discovery with commercialization. Headquartered in The Woodlands, Texas, Lexicon Pharmaceuticals serves the specialty pharmaceutical market through a focused pipeline designed for patients with serious, long-term medical needs.
Website2445 Technology Forest Boulevard
The Woodlands, TX, 77381
United States
The latest articles about LXRX.
Summary of Nov 18's posts. Generated by AI.
Summary of Jun 26's posts. Generated by AI.
Summary of Jan 29's posts. Generated by AI.
Summary of Jun 27's posts. Generated by AI.
Investors talking about LXRX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.